Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Development of Blood Vessels01:07

Development of Blood Vessels

1.6K
The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
1.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

7.3K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
7.3K
Hematopoiesis01:21

Hematopoiesis

9.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.5K
Veins of Head and Neck01:19

Veins of Head and Neck

6.5K
The blood drainage from the head and neck is primarily managed by three pairs of veins: the external jugular, internal jugular, and vertebral veins. The external jugular veins drain superficial scalp and face structures, passing over the sternocleidomastoid muscles to empty into the subclavian veins.
On the other hand, the vertebral veins, unlike their arterial counterparts, are not primarily responsible for brain drainage. Instead, they drain the cervical vertebrae, spinal cord, and some small...
6.5K
Skin Cancer01:30

Skin Cancer

6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Telocyte-derived pentraxin 3 enables vascular pruning as a key driver in infantile hemangioma regression.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Insights Into Poikiloderma With Neutropenia: Genotypic and Phenotypic Analysis of 90 Cases With a New Case Report.

American journal of medical genetics. Part A·2026
Same author

Higher Doses of Oral Propranolol for Resistant Infantile Haemangio-mas.

Acta dermato-venereologica·2026
Same author

Diagnosis and management of infantile hemangiomas: Tremendous advances over the last 15 years.

Presse medicale (Paris, France : 1983)·2025
Same author

Fulminant parvovirus B19 myocarditis in infants -report of three post-pandemic cases.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2025
Same author

Ustekinumab for pyoderma gangrenosum-like skin ulcerations in late-onset leukocyte adhesion deficiency.

The journal of allergy and clinical immunology. Global·2024
Same journal

Inherited retinal degenerations: clinical phenotypes and emerging therapies.

Lancet (London, England)·2026
Same journal

Documenting hospice care.

Lancet (London, England)·2026
Same journal

After the wood chipper.

Lancet (London, England)·2026
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

654

Infantile haemangioma.

Christine Léauté-Labrèze1, John I Harper2, Peter H Hoeger3

  • 1Department of Dematology, Pellegrin Children's Hospital, Bordeaux, France.

Lancet (London, England)
|January 17, 2017
PubMed
Summary
This summary is machine-generated.

Infantile haemangiomas, common benign infant tumors, often resolve without treatment. Early intervention with oral propranolol is recommended for high-risk cases to prevent complications.

More Related Videos

A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

3.6K

Related Experiment Videos

Last Updated: Mar 8, 2026

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach
05:30

Laparoscopic Anatomical Right Hemihepatectomy via the In Situ Anterior Approach

Published on: August 8, 2025

654
A Patient-Derived Xenograft Model for Venous Malformation
06:51

A Patient-Derived Xenograft Model for Venous Malformation

Published on: June 15, 2020

5.8K
Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

3.6K

Area of Science:

  • Pediatric Oncology
  • Dermatology
  • Vascular Anomalies

Background:

  • Infantile haemangiomas (IHs) are the most common benign tumors in infancy, affecting 4.5% of newborns.
  • IHs typically grow rapidly in the first few weeks of life and then involute spontaneously.
  • While most IHs do not require treatment, certain cases necessitate intervention due to risks.

Purpose of the Study:

  • To outline the management of infantile haemangiomas.
  • To identify risk factors and indications for treatment of IHs.
  • To emphasize the role of early propranolol therapy.

Main Methods:

  • Review of current literature and clinical guidelines for infantile haemangioma management.
  • Identification of critical time points for monitoring IH growth.
  • Assessment of treatment indications and efficacy of oral propranolol.

Main Results:

  • 80% of IHs reach final size by 3 months of age, highlighting the need for early follow-up.
  • Indications for treatment include life-threatening IHs, functional risks (visual, feeding), ulceration, and cosmetic distortion.
  • Oral propranolol is the first-line treatment, demonstrating rapid shrinkage and requiring a minimum of 6 months of therapy.

Conclusions:

  • Early detection and monitoring are crucial for identifying at-risk infantile haemangiomas.
  • Oral propranolol is a safe and effective first-line treatment for IHs requiring intervention.
  • Timely initiation of propranolol therapy can prevent severe complications associated with infantile haemangiomas.